What is Mobocertinib: Uses, Dosage, Side Effects and More

Mobocertinib is a targeted cancer medication that specifically treats a rare type of lung cancer called non-small cell lung cancer (NSCLC). This medication works by blocking certain proteins that help cancer cells grow and spread throughout your body. It's designed for people whose cancer has a specific genetic change called an EGFR exon 20 insertion mutation, which affects how cancer cells behave and grow.

What is Mobocertinib?

Mobocertinib is a prescription medication that belongs to a class of drugs called tyrosine kinase inhibitors. Think of it as a targeted treatment that works like a key designed to fit a specific lock in cancer cells. This medication specifically targets cancer cells that have a particular genetic mutation, leaving your healthy cells largely unaffected.

The medication comes in capsule form and is taken by mouth once daily. It's a relatively new treatment option that was approved by the FDA in 2021 for patients with advanced or metastatic NSCLC. Your doctor will typically order genetic testing of your tumor tissue to confirm you have the right type of mutation before prescribing this medication.

What is Mobocertinib Used For?

Mobocertinib is used to treat adults with locally advanced or metastatic non-small cell lung cancer that has progressed after platinum-based chemotherapy. Specifically, it's prescribed for patients whose tumors have EGFR exon 20 insertion mutations, which occur in about 1-2% of all lung cancer cases.

Your oncologist might recommend this medication if your cancer has spread to other parts of your body or if previous treatments haven't been effective. The medication is designed to slow down cancer growth and may help shrink tumors in some patients. It's particularly valuable because it targets a specific genetic change that was previously difficult to treat with other medications.

How Does Mobocertinib Work?

Mobocertinib works by blocking specific proteins called EGFR (epidermal growth factor receptor) that send signals telling cancer cells to grow and divide. When these proteins are blocked, cancer cells can't receive the growth signals they need to multiply and spread.

This medication is considered a moderately strong targeted therapy. Unlike chemotherapy that affects all rapidly dividing cells, mobocertinib specifically targets cancer cells with the EGFR mutation. This targeted approach means it can be effective against the cancer while generally causing fewer side effects than traditional chemotherapy.

The medication needs to be taken consistently to maintain steady levels in your bloodstream. This helps ensure the cancer cells remain blocked from receiving growth signals throughout the day.

How Should I Take Mobocertinib?

Take mobocertinib exactly as prescribed by your doctor, typically once daily at the same time each day. You can take it with or without food, but try to be consistent with your choice to help your body absorb the medication predictably.

Swallow the capsules whole with a full glass of water. Don't crush, chew, or open the capsules, as this can affect how the medication is absorbed. If you have trouble swallowing capsules, talk to your healthcare team about strategies that might help.

It's important to take mobocertinib at roughly the same time each day to maintain steady levels in your system. Many patients find it helpful to link taking their medication to a daily routine, like having breakfast or brushing their teeth.

How Long Should I Take Mobocertinib For?

You'll typically continue taking mobocertinib for as long as it's helping control your cancer and you're tolerating it well. This is often referred to as "until disease progression or unacceptable toxicity" in medical terms.

Your doctor will monitor your response to the medication through regular scans and blood tests, usually every 6-8 weeks initially. Some patients may take mobocertinib for months or even years if it continues to be effective. The duration varies significantly from person to person based on how well the cancer responds and how you handle any side effects.

Never stop taking mobocertinib without discussing it with your oncologist first. Even if you're feeling better, the medication may still be working to control cancer growth that isn't visible or causing symptoms yet.

What Are the Side Effects of Mobocertinib?

Like all cancer medications, mobocertinib can cause side effects, though not everyone experiences them. Most side effects are manageable with proper monitoring and supportive care from your healthcare team.

The most common side effects you might experience include diarrhea, which affects about 9 out of 10 patients taking this medication. Here are the side effects that occur most frequently:

• Diarrhea (often the most bothersome side effect)
• Skin rash or dry skin
• Nausea and decreased appetite
• Mouth sores or pain
• Fatigue or weakness
• Nail changes or nail bed infections

These common side effects are usually mild to moderate and often improve as your body adjusts to the medication. Your healthcare team can provide medications and strategies to help manage these effects.

Some patients may experience more serious side effects that require immediate medical attention. While these are less common, it's important to be aware of them:

• Severe diarrhea that doesn't respond to treatment
• Signs of heart problems (chest pain, shortness of breath, irregular heartbeat)
• Severe skin reactions or infections
• Difficulty breathing or persistent cough
• Severe nausea or vomiting that prevents eating or drinking

Contact your healthcare team immediately if you experience any of these more serious symptoms. They can adjust your treatment plan or provide additional support to help you feel better.

Who Should Not Take Mobocertinib?

Mobocertinib isn't suitable for everyone, and your doctor will carefully evaluate whether it's right for you. This medication should not be used by people who are allergic to mobocertinib or any of its ingredients.

Certain medical conditions may make mobocertinib less safe or effective for you. Your doctor will consider these factors before prescribing this medication:

• Severe heart problems or recent heart attack
• Severe liver or kidney disease
• Active, uncontrolled infections
• Pregnancy or breastfeeding
• Certain other medications that may interact dangerously

If you're pregnant or planning to become pregnant, it's crucial to discuss this with your doctor. Mobocertinib can harm an unborn baby, so effective birth control is important during treatment and for some time after stopping the medication.

Mobocertinib Brand Name

Mobocertinib is sold under the brand name Exkivity. This is the name you'll see on your prescription bottle and medication packaging. Both names refer to the same medication, but Exkivity is the commercial name used by the pharmaceutical company.

When talking to your healthcare team or pharmacist, you can use either name, and they'll know exactly which medication you're referring to. Some insurance companies or pharmacies may list it under one name or the other on their systems.

Mobocertinib Alternatives

If mobocertinib isn't suitable for you or stops working effectively, your doctor may consider other treatment options. The choice of alternative depends on your specific situation, including your cancer's characteristics and your overall health.

Other targeted therapies that might be considered include amivantamab, which is also approved for EGFR exon 20 insertion mutations. Some patients might benefit from immunotherapy drugs or returning to chemotherapy combinations. Clinical trials investigating new treatments for this specific type of lung cancer may also be an option.

Your oncologist will discuss the best alternative approach based on your cancer's genetic profile, how you responded to previous treatments, and your current health status. Each treatment option has its own benefits and potential side effects to consider.

Is Mobocertinib Better Than Other EGFR Inhibitors?

Mobocertinib is specifically designed for EGFR exon 20 insertion mutations, which makes it different from other EGFR inhibitors like erlotinib or osimertinib. These other medications work better for different types of EGFR mutations, so it's not necessarily about one being "better" than another.

The advantage of mobocertinib is that it targets a specific mutation that was previously very difficult to treat effectively. For patients with EGFR exon 20 insertion mutations, mobocertinib often provides better results than the older EGFR inhibitors, which weren't designed to target this particular genetic change.

Your doctor will choose the most appropriate EGFR inhibitor based on your tumor's specific genetic profile. This personalized approach helps ensure you receive the treatment most likely to be effective for your particular type of cancer.